Cardiology Department, ZNA Hartcentrum - ZNA Middelheim, Antwerpen, Belgium.
Department of Internal Medicine, ZNA Middelheim, Antwerpen, Belgium.
Acta Clin Belg. 2021 Apr;76(2):136-143. doi: 10.1080/17843286.2019.1662572. Epub 2019 Sep 3.
Differential diagnosis between hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) is mandatory since the prognosis is very different, but not always possible as both diseases present with increased myocardial thickness and mass. Despite better knowledge of the pathophysiology of both HCM and CA, and new developments in diagnosis, many patients with cardiac involvement in systemic amyloidosis are still only diagnosed in an advanced stage. Improvements in non-invasive diagnostic methods such as ultrasound techniques and cardiac magnetic resonance imaging will eventually obviate the need for invasive studies in order to prove amyloid cardiomyopathy. Nevertheless, today, an endomyocardial biopsy still remains the golden standard. We present an 86-year-old man, diagnosed with hypertrophic cardiomyopathy, in whom echocardiography and cardiac magnetic resonance imaging strongly suggested amyloidosis to be the underlying cause. Interestingly, a new variant of the junctophilin 2 (JPH2) gene, related to hypertrophic cardiomyopathies, was found in our patient.
鉴别肥厚型心肌病(HCM)和心脏淀粉样变性(CA)非常必要,因为两者的预后截然不同,但并非总是可行,因为这两种疾病都表现为心肌增厚和心肌质量增加。尽管人们对 HCM 和 CA 的病理生理学有了更好的认识,并且在诊断方面有了新的进展,但许多系统性淀粉样变性患者的心脏受累仍仅在晚期才被诊断出来。超声技术和心脏磁共振成像等非侵入性诊断方法的改进最终将消除对有创性研究的需求,以证明淀粉样心肌病的存在。然而,时至今日,心内膜心肌活检仍然是金标准。我们介绍了一位 86 岁的男性患者,他被诊断为肥厚型心肌病,超声心动图和心脏磁共振成像强烈提示淀粉样变性是其潜在病因。有趣的是,我们的患者携带一种与肥厚型心肌病相关的新型连接蛋白 2(JPH2)基因突变。